LIVIVO - Search results -

Search results

Result 1 - 10 of total 13

Search options

Article ; Online: High-density lipoprotein as a therapeutic target: a systematic review.

Singh, Inder M / Shishehbor, Mehdi H / Ansell, Benjamin J

2007 Volume 298, Issue 7, Page(s) 786–798

Abstract: ... gaining substantial interest as a therapeutic target.: Objectives: To review the current and emerging ... strategies that modify high-density lipoproteins (HDLs).: Data sources: Systematic search of English ... Context: High-density lipoprotein cholesterol (HDL-C) is a cardiovascular risk factor that is ...

Abstract	Context: High-density lipoprotein cholesterol (HDL-C) is a cardiovascular risk factor that is gaining substantial interest as a therapeutic target. Objectives: To review the current and emerging strategies that modify high-density lipoproteins (HDLs). Data sources: Systematic search of English-language literature (1965-May 2007) in MEDLINE and the Cochrane database, using the key words HDL-C and apolipoprotein A-I and the subheadings reverse cholesterol transport, CVD [cardiovascular disease] prevention and control, drug therapy, and therapy; review of presentations made at major cardiovascular meetings from 2003-2007; and review of ongoing trials from ClinicalTrials.gov and current guidelines from major cardiovascular societies. Study selection and data extraction: Study selection was prioritized to identify randomized controlled trials over meta-analyses over mechanistic studies; identified studies also included proof-of-concept studies and key phase 1 through 3 trials of novel agents. Study eligibility was assessed by 2 authors; disagreements were resolved by consensus with the third. Data synthesis: Of 754 studies identified, 31 randomized controlled trials met the inclusion criteria. Currently available therapeutic and lifestyle strategies, when optimized, increase HDL-C levels by 20% to 30%. While basic and small pilot studies have shown promise, proof that increasing HDL-C levels confers a reduction in major cardiovascular outcomes independent of changes in levels of low-density lipoprotein cholesterol or triglycerides has been more elusive. Some novel therapeutic agents in human studies appear to effectively increase HDL-C levels, whereas other novel strategies that target HDL metabolism or function may have minimal effect on HDL-C levels. Conclusions: At present there is modest evidence to support aggressively increasing HDL-C levels in addition to what is achieved by lifestyle modification alone. Ongoing clinical trials that target specific pathways in HDL metabolism may help expand cardiovascular treatment options.
MeSH term(s)	Anticholesteremic Agents/pharmacology ; Anticholesteremic Agents/therapeutic use ; Apolipoprotein A-I/blood ; Atherosclerosis/blood ; Atherosclerosis/epidemiology ; Biological Transport ; Cardiovascular Diseases/blood ; Cardiovascular Diseases/therapy ; Cholesterol, HDL/blood ; Cholesterol, HDL/metabolism ; Humans ; Lipoproteins, HDL/blood ; Lipoproteins, HDL/metabolism ; Macrophages/metabolism ; Risk Factors ; Risk Reduction Behavior
Chemical Substances	Anticholesteremic Agents ; Apolipoprotein A-I ; Cholesterol, HDL ; Lipoproteins, HDL
Language	English
Publishing date	2007-09-25
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review ; Systematic Review
ZDB-ID	2958-0
ISSN	1538-3598 ; 0254-9077 ; 0002-9955 ; 0098-7484
ISSN (online)	1538-3598
ISSN	0254-9077 ; 0002-9955 ; 0098-7484
DOI	10.1001/jama.298.7.786
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.88: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors.

Spagnuolo, Catherine M / Hegele, Robert A

Expert opinion on pharmacotherapy

2023 Volume 24, Issue 9, Page(s) 1013–1020

Abstract: ... low-density lipoprotein cholesterol are relatively ineffective. Apolipoprotein (apo) C-III is a new pharmacological target to reduce ... reflect high levels of triglyceride-rich lipoproteins, against which lipid-lowering therapies that reduce ... cardiovascular disease, olezarsen, triglycerides, and volanesorsen; study types: clinical trials, systematic reviews, and ...

Abstract	Introduction: Mild-to-moderate hypertriglyceridemia (HTG) is commonly encountered and is associated with atherosclerotic cardiovascular disease (ASCVD). Elevated plasma triglyceride (TG) levels reflect high levels of triglyceride-rich lipoproteins, against which lipid-lowering therapies that reduce low-density lipoprotein cholesterol are relatively ineffective. Apolipoprotein (apo) C-III is a new pharmacological target to reduce triglycerides and potentially also cardiovascular disease risk. Areas covered: Here, we evaluate current lipid-lowering therapies and their effect on TG levels; genetic, pre-clinical, cellular, molecular biology, and translational studies that emphasize the importance of apo C-III in the metabolism of TG-rich lipoproteins and ASCVD risk; and clinical trials of pharmacotherapies that reduce TG levels via apo C-III inhibition. The PubMed database was searched using terms: apolipoprotein C-III, ARO-APOC3, atherosclerotic cardiovascular disease, olezarsen, triglycerides, and volanesorsen; study types: clinical trials, systematic reviews, and meta-analyses; and time criterion 2005 to present. Expert opinion: Apo C-III inhibition is a promising treatment approach for adults with mild-to-moderate HTG and either established atherosclerotic cardiovascular disease or its risk factors. Biologic agents such as volanesorsen, olezarsen, and ARO-APOC3 significantly reduce plasma levels of apo C-III and TG, although data on cardiovascular outcomes are lacking. Volanesorsen is associated with thrombocytopenia in patients with severe HTG, but other agents appear to be better tolerated. Clinical trials with long-term follow-up of cardiovascular outcomes will establish the validity of apo C-III inhibition.
MeSH term(s)	Adult ; Humans ; Apolipoprotein C-III ; Cardiovascular Diseases/etiology ; Cardiovascular Diseases/prevention & control ; Hyperlipidemias/drug therapy ; Hypertriglyceridemia ; Lipoproteins ; Triglycerides ; Atherosclerosis
Chemical Substances	Apolipoprotein C-III ; Lipoproteins ; Triglycerides
Language	English
Publishing date	2023-04-28
Publishing country	England
Document type	Journal Article
ZDB-ID	2001535-5
ISSN	1744-7666 ; 1465-6566
ISSN (online)	1744-7666
ISSN	1465-6566
DOI	10.1080/14656566.2023.2206015
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5130: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Vegetarian Dietary Patterns and Cardiometabolic Risk in People With or at High Risk of Cardiovascular Disease: A Systematic Review and Meta-analysis.

Wang, Tian / Kroeger, Cynthia M / Cassidy, Sophie / Mitra, Sayan / Ribeiro, Rosilene V / Jose, Shane / Masedunskas, Andrius / Senior, Alistair M / Fontana, Luigi

JAMA network open

2023 Volume 6, Issue 7, Page(s) e2325658

Abstract: ... low-density lipoprotein cholesterol (LDL-C), hemoglobin A1c (HbA1c), systolic blood pressure (SBP), and body weight in people with or ... improvements in LDL-C, HbA1c and body weight beyond standard therapy in individuals at high risk of CVDs ... but their effects on people at high risk of cardiovascular diseases (CVDs) remain inconclusive.: Objective ...

Abstract	Importance: Plant-based diets are known to improve cardiometabolic risk in the general population, but their effects on people at high risk of cardiovascular diseases (CVDs) remain inconclusive. Objective: To assess the association of vegetarian diets with major cardiometabolic risk factors, including low-density lipoprotein cholesterol (LDL-C), hemoglobin A1c (HbA1c), systolic blood pressure (SBP), and body weight in people with or at high risk of CVDs. Data sources: This meta-analysis was registered before the study was conducted. Systematic searches performed included Embase, MEDLINE, CINAHL, and CENTRAL from inception until July 31, 2021. Study selection: Eligible randomized clinical trials (RCTs) that delivered vegetarian diets in adults with or at high risk of CVDs and measured LDL-C, HbA1c or SBP were included. Of the 7871 records screened, 29 (0.4%; 20 studies) met inclusion criteria. Data extraction and synthesis: Two reviewers independently extracted data including demographics, study design, sample size, and diet description, and performed risk of bias assessment. A random-effects model was used to assess mean changes in LDL-C, HbA1c, SBP, and body weight. The overall certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) tool. Main outcomes and measures: Mean differences between groups in changes (preintervention vs postintervention) of LDL-C, HbA1c, and SBP; secondary outcomes were changes in body weight and energy intake. Results: Twenty RCTs involving 1878 participants (range of mean age, 28-64 years) were included, and mean duration of intervention was 25.4 weeks (range, 2 to 24 months). Four studies targeted people with CVDs, 7 focused on diabetes, and 9 included people with at least 2 CVD risk factors. Overall, relative to all comparison diets, meta-analyses showed that consuming vegetarian diets for an average of 6 months was associated with decreased LDL-C, HbA1c, and body weight by 6.6 mg/dL (95% CI, -10.1 to -3.1), 0.24% (95% CI, -0.40 to -0.07), and 3.4 kg (95% CI, -4.9 to -2.0), respectively, but the association with SBP was not significant (-0.1 mm Hg; 95% CI, -2.8 to 2.6). The GRADE assessment showed a moderate level of evidence for LDL-C and HbA1c reduction. Conclusions and relevance: In this study, consuming a vegetarian diet was associated with significant improvements in LDL-C, HbA1c and body weight beyond standard therapy in individuals at high risk of CVDs. Additional high-quality trials are warranted to further elucidate the effects of healthy plant-based diets in people with CVDs.
MeSH term(s)	Adult ; Humans ; Middle Aged ; Cardiovascular Diseases ; Cholesterol, LDL ; Glycated Hemoglobin ; Vegetarians ; Research Design ; Body Weight
Chemical Substances	Cholesterol, LDL ; Glycated Hemoglobin
Language	English
Publishing date	2023-07-03
Publishing country	United States
Document type	Meta-Analysis ; Systematic Review ; Journal Article ; Research Support, Non-U.S. Gov't
ISSN	2574-3805
ISSN (online)	2574-3805
DOI	10.1001/jamanetworkopen.2023.25658
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Proportion of High-Risk/Very High-Risk Patients in Europe with Low-Density Lipoprotein Cholesterol at Target According to European Guidelines: A Systematic Review.

Bruckert, Eric / Parhofer, Klaus Georg / Gonzalez-Juanatey, Jose Ramon / Nordestgaard, Børge / Arca, Marcello / Giovas, Periklis / Ray, Kausik

Advances in therapy

2020 Volume 37, Issue 5, Page(s) 1724–1736

Abstract: Objective: Assess achievement of low-density lipoprotein cholesterol (LDL-C) targets in European ... literature review.: Data sources: Medline, EMBASE, Cumulated Index to Nursing and Allied Health Literature ... Eligibility criteria: Observational studies reporting LDL-C levels/target attainment, measured between 1 ...

Abstract	Objective: Assess achievement of low-density lipoprotein cholesterol (LDL-C) targets in European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) guidelines. Design: Systematic literature review. Data sources: Medline, EMBASE, Cumulated Index to Nursing and Allied Health Literature. Eligibility criteria: Observational studies reporting LDL-C levels/target attainment, measured between 1 August 2006 to 31 August 2017, in European adults with established cardiovascular disease (CVD), diabetes with target organ damage, familial hypercholesterolaemia (FH) or 10-year risk of fatal CVD ≥ 5% (assessed by Systematic Coronary Risk Evaluation [SCORE]). Data extraction and synthesis: Two reviewers independently extracted relevant studies and assessed study quality using the Risk of Bias for Non-Randomised Studies-Interventions (ROBINS-I) tool. Primary outcome was the proportion of patients achieving LDL-C targets in the 2011/2016 ESC/EAS guidelines. Where available, patient characteristics were presented as means weighted by sample size. The proportions of patients achieving LDL-C targets in the 5 years before and after publication of the 2011 guidelines were compared using a chi-square test. Results: Across 81 eligible studies (303,534 patients), achievement of LDL-C < 1.8 mmol/L was poor among patients with established CVD (16%; range 9-56%) and at very high risk of CVD (SCORE ≥ 10% [18%; 14-25%]). In individuals with FH, SCORE 5-10%, or diabetes and target organ damage, LDL-C < 2.5 mmol/L was achieved by 15% (9-22%), 46% (21-55%) and 13% (6-34%), respectively. Comparing the 5 years before/after publication of the 2011 guidelines, target achievement increased significantly over time but remained suboptimal (LDL-C < 1.8, 22% versus 15%; LDL-C < 2.5, 68% versus 61%; both p < 0.001; established CVD group only). Conclusions: These data show suboptimal LDL-C control among European patients at high risk of CVD. Those at greatest overall risk (clinically established CVD or at least a 10% 10-year risk of fatal CVD) had the lowest achievement of 2011/2016 EAS/ESC LDL-C targets. With lower LDL-C targets advocated in 2019 ESC/EAS guidelines, this unmet need will increase. Protocol registration: PROSPERO registration number; CRD77844.
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Cardiovascular Diseases/prevention & control ; Cholesterol, LDL/blood ; Cholesterol, LDL/standards ; Europe/epidemiology ; Female ; Humans ; Hyperlipoproteinemia Type II/epidemiology ; Hyperlipoproteinemia Type II/physiopathology ; Hyperlipoproteinemia Type II/prevention & control ; Male ; Medication Therapy Management/standards ; Middle Aged ; Practice Guidelines as Topic/standards ; Risk Factors
Chemical Substances	Cholesterol, LDL
Language	English
Publishing date	2020-03-21
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Systematic Review
ZDB-ID	632651-1
ISSN	1865-8652 ; 0741-238X
ISSN (online)	1865-8652
ISSN	0741-238X
DOI	10.1007/s12325-020-01285-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2101: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis.

Hodkinson, Alexander / Tsimpida, Dialechti / Kontopantelis, Evangelos / Rutter, Martin K / Mamas, Mamas A / Panagioti, Maria

BMJ (Clinical research ed.)

2022 Volume 376, Page(s) e067731

Abstract: ... high density lipoprotein cholesterol (non-HDL-C) for the prevention of cardiovascular disease in people ... with diabetes.: Design: Systematic review and network meta-analysis.: Data sources: Medline, Cochrane ... are most effective by reducing non-HDL-C in patients with diabetes.: Systematic review registration ...

Abstract	Objective: To compare the efficacy of different statin treatments by intensity on levels of non-high density lipoprotein cholesterol (non-HDL-C) for the prevention of cardiovascular disease in people with diabetes. Design: Systematic review and network meta-analysis. Data sources: Medline, Cochrane Central Register of Controlled Trials, and Embase from inception to 1 December 2021. Review methods: Randomised controlled trials comparing different types and intensities of statins, including placebo, in adults with type 1 or type 2 diabetes mellitus were included. The primary outcome was changes in levels of non-HDL-C, calculated from measures of total cholesterol and HDL-C. Secondary outcomes were changes in levels of low density lipoprotein cholesterol (LDL-C) and total cholesterol, three point major cardiovascular events (non-fatal stroke, non-fatal myocardial infarction, and death related to cardiovascular disease), and discontinuations because of adverse events. A bayesian network meta-analysis of statin intensity (low, moderate, or high) with random effects evaluated the treatment effect on non-HDL-C by mean differences and 95% credible intervals. Subgroup analysis of patients at greater risk of major cardiovascular events was compared with patients at low or moderate risk. The confidence in network meta-analysis (CINeMA) framework was applied to determine the certainty of evidence. Results: In 42 randomised controlled trials involving 20 193 adults, 11 698 were included in the meta-analysis. Compared with placebo, the greatest reductions in levels of non-HDL-C were seen with rosuvastatin at high (-2.31 mmol/L, 95% credible interval -3.39 to -1.21) and moderate (-2.27, -3.00 to -1.49) intensities, and simvastatin (-2.26, -2.99 to -1.51) and atorvastatin (-2.20, -2.69 to -1.70) at high intensity. Atorvastatin and simvastatin at any intensity and pravastatin at low intensity were also effective in reducing levels of non-HDL-C. In 4670 patients at greater risk of a major cardiovascular events, atorvastatin at high intensity showed the largest reduction in levels of non-HDL-C (-1.98, -4.16 to 0.26, surface under the cumulative ranking curve 64%). Simvastatin (-1.93, -2.63 to -1.21) and rosuvastatin (-1.76, -2.37 to -1.15) at high intensity were the most effective treatment options for reducing LDL-C. Significant reductions in non-fatal myocardial infarction were found for atorvastatin at moderate intensity compared with placebo (relative risk=0.57, confidence interval 0.43 to 0.76, n=4 studies). No significant differences were found for discontinuations, non-fatal stroke, and cardiovascular deaths. Conclusions: This network meta-analysis indicated that rosuvastatin, at moderate and high intensity doses, and simvastatin and atorvastatin, at high intensity doses, were most effective at moderately reducing levels of non-HDL-C in patients with diabetes. Given the potential improvement in accuracy in predicting cardiovascular disease when reduction in levels of non-HDL-C is used as the primary target, these findings provide guidance on which statin types and intensities are most effective by reducing non-HDL-C in patients with diabetes. Systematic review registration: PROSPERO CRD42021258819.
MeSH term(s)	Adult ; Bayes Theorem ; Cardiovascular Diseases/chemically induced ; Cholesterol ; Diabetes Mellitus, Type 2/chemically induced ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects ; Network Meta-Analysis
Chemical Substances	Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Cholesterol (97C5T2UQ7J)
Language	English
Publishing date	2022-03-24
Publishing country	England
Document type	Journal Article ; Meta-Analysis ; Research Support, Non-U.S. Gov't ; Systematic Review
ZDB-ID	1362901-3
ISSN	1756-1833 ; 0959-8154 ; 0959-8146 ; 0959-8138 ; 0959-535X ; 1759-2151
ISSN (online)	1756-1833
ISSN	0959-8154 ; 0959-8146 ; 0959-8138 ; 0959-535X ; 1759-2151
DOI	10.1136/bmj-2021-067731
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.10: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Effects of high-density lipoprotein targeting treatments on cardiovascular outcomes: A systematic review and meta-analysis.

Riaz, Haris / Khan, Safi U / Rahman, Hammad / Shah, Nishant P / Kaluski, Edo / Lincoff, A Michael / Nissen, Steven E

European journal of preventive cardiology

2018 Volume 26, Issue 5, Page(s) 533–543

Abstract: Background: The effects of increasing high-density lipoprotein cholesterol on cardiovascular ... density lipoprotein cholesterol modifiers (niacin, fibrates and cholesteryl ester transfer protein ... density lipoprotein cholesterol modifying treatments had no significant effect on cardiovascular mortality ...

Abstract	Background: The effects of increasing high-density lipoprotein cholesterol on cardiovascular outcomes remain uncertain. Design: We conducted a meta-analysis to investigate the effects of high-density lipoprotein cholesterol modifiers (niacin, fibrates and cholesteryl ester transfer protein inhibitors) on cardiovascular outcomes. Methods: Thirty-one randomized controlled trials (154,601 patients) with a follow-up of 6 months or more and a sample size of 100 or more patients were selected using MEDLINE, EMBASE and CENTRAL database (inception January 2018). Results: High-density lipoprotein cholesterol modifiers had no statistically significant effect on cardiovascular mortality in terms of relative risk (RR) (RR 0.94, 95% confidence interval (CI) 0.89-1.00, P = 0.05, I Conclusion: The use of high-density lipoprotein cholesterol modifying treatments had no significant effect on cardiovascular mortality, stroke or all-cause mortality. The beneficial effect on myocardial infarction was lost when drugs were used with statin therapy.
MeSH term(s)	Adult ; Aged ; Biomarkers/blood ; Cardiovascular Diseases/diagnosis ; Cardiovascular Diseases/mortality ; Cardiovascular Diseases/prevention & control ; Cholesterol Ester Transfer Proteins/antagonists & inhibitors ; Cholesterol Ester Transfer Proteins/metabolism ; Cholesterol, HDL/blood ; Dyslipidemias/blood ; Dyslipidemias/diagnosis ; Dyslipidemias/drug therapy ; Dyslipidemias/mortality ; Female ; Humans ; Hypolipidemic Agents/adverse effects ; Hypolipidemic Agents/therapeutic use ; Male ; Middle Aged ; Niacin/adverse effects ; Niacin/therapeutic use ; Randomized Controlled Trials as Topic ; Risk Assessment ; Risk Factors ; Treatment Outcome ; Up-Regulation
Chemical Substances	Biomarkers ; CETP protein, human ; Cholesterol Ester Transfer Proteins ; Cholesterol, HDL ; Hypolipidemic Agents ; Niacin (2679MF687A)
Language	English
Publishing date	2018-12-06
Publishing country	England
Document type	Journal Article ; Meta-Analysis ; Systematic Review
ZDB-ID	2626011-6
ISSN	2047-4881 ; 2047-4873
ISSN (online)	2047-4881
ISSN	2047-4873
DOI	10.1177/2047487318816495
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4686: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy.

Lorenzi, Maria / Ambegaonkar, Baishali / Baxter, Carl A / Jansen, Jeroen / Zoratti, Michael J / Davies, Glenn

Clinical research in cardiology : official journal of the German Cardiac Society

2018 Volume 108, Issue 5, Page(s) 487–509

Abstract: ... with hypercholesterolemia, statin monotherapy is often insufficient to achieve target low-density lipoprotein ... Purpose: While statins are used as first-line treatments for high-risk patients ... at high risk of cardiovascular disease (CVD) and who had been previously treated with a statin.: Methods ...

Abstract	Purpose: While statins are used as first-line treatments for high-risk patients with hypercholesterolemia, statin monotherapy is often insufficient to achieve target low-density lipoprotein cholesterol (LDL-C) levels. Second-line treatment options include up-titration of statin dose, switching to a more potent statin, or combination therapy, e.g., with ezetimibe. The aim of this study was to evaluate the efficacy of adding ezetimibe to simvastatin, atorvastatin, or rosuvastatin monotherapy versus doubling the dosage or switching to a higher-potency statin in a population of patients with hypocholesterolemia at high risk of cardiovascular disease (CVD) and who had been previously treated with a statin. Methods: A systematic literature search was performed and evidence bases were established for populations of atorvastatin-, simvastatin-, and rosuvastatin-experienced patients using eligible randomized controlled trials (RCTs). Based on the available data, we constructed networks of evidence and conducted a Bayesian network meta-analysis (NMA) within each statin population. The primary outcome of interest was percent change from baseline in LDL-C. Changes in total cholesterol were explored as a secondary outcome. Findings: Across all patient populations, 35 RCTs were identified and included in the evidence base. Among patients on simvastatin therapy, the addition of ezetimibe resulted in a mean difference (MD) in LDL-C of - 13.62% (95% CrI - 19.99, - 6.91; see table below) compared to doubling the starting dose of simvastatin. In the population of patients on atorvastatin therapy, the addition of ezetimibe resulted in an MD in LDL-C of - 14.71% (95% CrI - 16.46, - 12.95) compared to doubling the starting dose of atorvastatin. The addition of ezetimibe to rosuvastatin resulted in an MD in LDL-C of - 14.96% (95% CrI - 17.79, - 12.11), compared to doubling the starting rosuvastatin dose. Similar trends were observed for changes in total cholesterol. Implications: Given the available data, the addition of ezetimibe to ongoing simvastatin, atorvastatin, or rosuvastatin monotherapy offers greater reduction in LDL-C among patients at high risk of CVD compared to doubling the initial statin dose.
MeSH term(s)	Anticholesteremic Agents/therapeutic use ; Bayes Theorem ; Biomarkers/blood ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/etiology ; Cardiovascular Diseases/prevention & control ; Cholesterol, LDL/blood ; Cholesterol, LDL/drug effects ; Drug Therapy, Combination ; Ezetimibe/therapeutic use ; Global Health ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Hypercholesterolemia/complications ; Hypercholesterolemia/drug therapy ; Incidence ; Risk Factors
Chemical Substances	Anticholesteremic Agents ; Biomarkers ; Cholesterol, LDL ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Ezetimibe (EOR26LQQ24)
Language	English
Publishing date	2018-10-09
Publishing country	Germany
Document type	Journal Article ; Meta-Analysis ; Systematic Review
ZDB-ID	2213295-8
ISSN	1861-0692 ; 1861-0684
ISSN (online)	1861-0692
ISSN	1861-0684
DOI	10.1007/s00392-018-1379-z
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Ui IV Zs 10: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: High-density lipoprotein cholesterol efflux capacity is inversely associated with cardiovascular risk: a systematic review and meta-analysis.

Qiu, Chengfeng / Zhao, Xiang / Zhou, Quan / Zhang, Zhen

Lipids in health and disease

2017 Volume 16, Issue 1, Page(s) 212

Abstract: Background: A low plasma level of high-density lipoprotein (HDL) cholesterol (HDL-C) is associated ... therapeutic targeting HDL metabolism. ...

Abstract	Background: A low plasma level of high-density lipoprotein (HDL) cholesterol (HDL-C) is associated with cardiovascular risk. A key cardioprotective property of HDL is cholesterol efflux capacity (CEC), the ability of HDL to accept cholesterol from macrophages. In this study, we aimed to identify the predictive value of CEC for cardiovascular risk. Methods: The relative risks (RRs) and 95% confidence intervals (CIs) were pooled to analyze the association between CEC and the incidence of cardiovascular events and all-cause mortality. The odds ratios (ORs) and 95% CIs were pooled to estimate the association of CEC and the prevalence of cardiovascular events. Results: A total of 15 studies were included. Results showed that the highest CEC was significantly associated with a reduced risk of cardiovascular events incidents compared to the lowest CEC (RR, 0.56; 95% CI, 0.37 to 0.85; I Conclusions: Findings from this meta-analysis suggest that HDL-mediated CEC is inversely associated with cardiovascular risk, which appears to be independent of HDL concentration. The growing understanding of CEC and its role in cardiovascular risk decrease may improve the accuracy of cardiovascular risk prediction and also open important avenues to develop novel therapeutic targeting HDL metabolism.
MeSH term(s)	Adult ; Aged ; Cardiovascular Diseases/blood ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/etiology ; Cardiovascular Diseases/metabolism ; Female ; Humans ; Lipoproteins, HDL/blood ; Lipoproteins, HDL/metabolism ; Male ; Middle Aged ; Risk Factors
Chemical Substances	Lipoproteins, HDL
Language	English
Publishing date	2017-11-10
Publishing country	England
Document type	Journal Article ; Meta-Analysis ; Review
ISSN	1476-511X
ISSN (online)	1476-511X
DOI	10.1186/s12944-017-0604-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Systematic review of CETP inhibitors for increasing high-density lipoprotein cholesterol: where do these agents stand in the approval process?

Bishop, Bryan M

American journal of therapeutics

2015 Volume 22, Issue 2, Page(s) 147–158

Abstract: The role that low levels of high-density lipoprotein cholesterol (HDL-C) plays ... by a greater amount and both have a significant effect on low-density lipoprotein cholesterol). It remains ... an increase in mortality, although this was attributed to off-target toxicity. Dalcetrapib was found to be ...

Abstract	The role that low levels of high-density lipoprotein cholesterol (HDL-C) plays in coronary artery disease and ischemic heart disease is well established. As such, therapies targeting low HDL-C levels have been of great therapeutic interest. These therapies include nonpharmacological methods such as exercise, tobacco cessation, weight reduction, moderate alcohol intake, and increasing dietary monounsaturated fatty acids and polyunsaturated fatty acids. Additionally, pharmacological methods of increasing HDL-C have been of great interest, with 2 classes of drugs, fibric acid derivatives and nicotinic acid, and have mixed trial results when used on top of standard lipid therapy. However, a new class of medications, cholesteryl ester transfer protein inhibitors, has shown increases in HDL-C of over 100%. However, early trial results with torcetrapib showed an increase in mortality, although this was attributed to off-target toxicity. Dalcetrapib was found to be safer than torcetrapib, but data released in 2012 showed no additional benefit in patients suffering an acute coronary syndrome event. Two newer agents, anacetrapib and evacetrapib, in early-phase clinical trials have shown to be safer than torcetrapib and significantly more potent than dalcetrapib (both increase HDL-C by a greater amount and both have a significant effect on low-density lipoprotein cholesterol). It remains to be seen whether the use of cholesteryl ester transfer protein inhibitors will result in clinical benefit in large, randomized double-blind trials and whether any agents in this class will ever be approved for clinical use.
MeSH term(s)	Animals ; Anticholesteremic Agents/adverse effects ; Anticholesteremic Agents/pharmacology ; Anticholesteremic Agents/therapeutic use ; Cholesterol Ester Transfer Proteins/antagonists & inhibitors ; Cholesterol, HDL/drug effects ; Clinical Trials as Topic ; Drug Approval ; Humans
Chemical Substances	Anticholesteremic Agents ; Cholesterol Ester Transfer Proteins ; Cholesterol, HDL
Language	English
Publishing date	2015-03
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1280786-2
ISSN	1536-3686 ; 1075-2765
ISSN (online)	1536-3686
ISSN	1075-2765
DOI	10.1097/MJT.0b013e31828b8463
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4351: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Reconstituted high density lipoprotein-based nanoparticles: an overview of applications in regenerative medicine, preparation, evaluation and future trends.

Wang, Xiaoyi / Zhou, Jianping / Wang, Wei

Current pharmaceutical design

2014 Volume 21, Issue 12, Page(s) 1529–1544

Abstract: Reconstituted high density lipoprotein (rHDL) is an excellent and highly biocompatible nanovector ... mimicking the physical, chemical as well as physiological properties of native high density lipoprotein (HDL ... for regenerative medicine. As such, a systematic review of this promising carrier will be of great importance for subsequent ...

Abstract	Reconstituted high density lipoprotein (rHDL) is an excellent and highly biocompatible nanovector mimicking the physical, chemical as well as physiological properties of native high density lipoprotein (HDL), and is originally widely used as the substitute in HDL related studies. Over the past decades, rHDL has increasingly been exploited into vehicles for targeted delivery of numerous drugs, therapeutic genes, etc., and is playing a more and more important role in drug delivery design for regenerative medicine. As such, a systematic review of this promising carrier will be of great importance for subsequent studies. In this article, the term "rHDL-based nanoparticles (rHDLbased NPs)" is employed to refer to rHDL and its modified form. This review highlights four aspects of rHDL-based NPs: current applications in regenerative medicine, preparation methods, conventional evaluation methods, and future trends on co-delivery of drugs for synergic effects.
MeSH term(s)	Animals ; Drug Delivery Systems ; Drug Design ; Humans ; Lipoproteins, HDL/chemistry ; Nanoparticles ; Regenerative Medicine/methods
Chemical Substances	Lipoproteins, HDL
Language	English
Publishing date	2014-11-20
Publishing country	United Arab Emirates
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review ; Systematic Review
ZDB-ID	1304236-1
ISSN	1873-4286 ; 1381-6128
ISSN (online)	1873-4286
ISSN	1381-6128
DOI	10.2174/1381612821666150115130102
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4714: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito